A novel candidate antigen of Plasmodium vivax vaccine: Immunogenicity and immune effect of PvTRAg-26/29 related to infected red blood cell membrane

The widespread transmission and high mortality rate of malaria as well as increasing antimalaria drug resistance urge the need for the development of malaria vaccines. However, current vaccines development have been limited to parasitic organism related antigens polymorphism, low and/or short immunogenicity and so on. The development of a successful multivalent malaria vaccine therefore requires identification of novel potential vaccine antigens. It has been reported that Tryptophan-rich antigens (TRAgs) in Plasmodium falciparum are proven to have protection for merozoite invasion. While, Plasmodium vivax TRAgs (PvTRAgs) have been found to include more family members than other malarial species. PvTRAgs contain positionally conserved tryptophan residues in a TR domain. Several of these proteins have erythrocyte binding activity. Based on the previous data, PvTRAg-26/29, which were proved as infected RBC membrane associated antigens, have high, stable and longlasting antigenicity among South Eastern Asian patients that strongly suggest PvTRAg-26/29 as potential vaccine candidates. Thus, In the present project, to adequately evaluate the immunogenicity and its vaccine potential, its immunogenicity was assessed by stimulating patients’ PBMCs and immunizing BALB/c mice using PvTRAg-26/29 as well as PvTRAg-29/rPvCSP-C recombinant protein. So far, no relevant approach has been available. This study will further firm up the basis for understanding the immune mechanism of PvTRAgs and may provide vaccine candidate(s) for new malaria vaccine design.

Immunology
P. vivax
Vaccines

Jan 2017 — Dec 2019

$25,886

China